608TiPBRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701). (23rd October 2018) - Masuishi, T; Taniguchi, H; Kotani, D; Bando, H; Komatsu, Y; Yamaguchi, K; Nakajima, T E; Satoh, T; Nishina, T; Esaki, T; Wakabayashi, M; Nomura, S; et al.